{"entity":{"id":"sumitomo-pharma","kind":"company","name":"Sumitomo Pharma (Myovant)","aka":[],"tldr":"Sumitomo Pharma makes Orgovyx (relugolix), the first oral GnRH antagonist for prostate cancer.","summary":"Sumitomo Pharma, based in Osaka, is the Japanese pharmaceutical company that makes Orgovyx, or relugolix, the first oral GnRH antagonist for prostate cancer, after acquiring Myovant Sciences in 2023. In the HERO trial relugolix gave rapid and reversible testosterone suppression without the flare seen with GnRH agonists, and with fewer major cardiovascular events in that trial. OnCo links it to prostate cancer and to the relugolix drug record. Whether an oral daily tablet improves adherence and outcomes over long-acting injections in routine practice, rather than in a trial, is the open question. Relugolix has its own page with the approval detail.","asOf":"2026-09-06","links":[{"label":"Official website","url":"https://www.sumitomo-pharma.com"}],"tags":[],"related":[],"cancers":["prostate"],"sections":["hormonal"],"technologies":[],"targets":[],"drugs":["relugolix","amrubicin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05862272","nct06526819","nct04988555"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Osaka","country":"JP","companyType":"pharma","website":"https://www.sumitomo-pharma.com","investors":[],"funding":[]},"route":"/companies/sumitomo-pharma/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"hormonal","kind":"section","name":"Hormonal Therapy","route":"/fronts/hormonal/"}],"drug":[{"id":"amrubicin","kind":"drug","name":"Amrubicin","route":"/drugs/amrubicin/"},{"id":"napabucasin","kind":"drug","name":"Napabucasin","route":"/drugs/napabucasin/"},{"id":"relugolix","kind":"drug","name":"Relugolix","route":"/drugs/relugolix/"}],"trial":[{"id":"nct04988555","kind":"trial","name":"A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)","route":"/trials/nct04988555/"},{"id":"nct05862272","kind":"trial","name":"A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis","route":"/trials/nct05862272/"},{"id":"canstem111p","kind":"trial","name":"CanStem111P","route":"/trials/canstem111p/"},{"id":"hero","kind":"trial","name":"HERO","route":"/trials/hero/"},{"id":"nct06526819","kind":"trial","name":"SMP-3124LP in Adults With Advanced Solid Tumors","route":"/trials/nct06526819/"}]}}